InvestorsObserver is giving ProQR Therapeutics NV (PRQR) an Analyst Rating Rank of 25, meaning PRQR is ranked higher by analysts than 25% of stocks. The average price target for PRQR is $2.94 and analyst’s rate the stock as a Buy.
Wall Street analysts are rating PRQR a Buy today. Find out what this means to you and get the rest of the rankings on PRQR!
Why are Analyst Ratings Important?
Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve.
InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.
What's Happening With ProQR Therapeutics NV Stock Today?
ProQR Therapeutics NV (PRQR) stock is unmoved 0.07% while the S&P 500 has gained 0.83% as of 11:24 AM on Tuesday, May 3. PRQR is unmoved $0.00 from the previous closing price of $0.70 on volume of 1,099,850 shares. Over the past year the S&P 500 has fallen -0.07% while PRQR has fallen -88.99%. PRQR lost -$1.01 per share the over the last 12 months.
Click Here to get the full Stock Report for ProQR Therapeutics NV stock.